The Role of Radiotherapy for the Management of Non-melanoma Skin Cancer in Denmark.

Summary

The goal of this observational study is to learn about the long-term effects of radiotherapy for people who were treated for non-melanoma skin cancer (NMSC) in the head and neck area. The study focuses on adults who finished radiotherapy at least two years ago.

The main questions we aim to answer are:

How satisfied are participants with the cosmetic result of their treatment?

What skin changes do healthcare professionals observe at the treated area?

How many participants have experienced a recurrence or developed a new skin cancer, since treatment?

Participants will be invited to:

Attend one extra hospital visit at least two years after they finished radiotherapy

Answer a short questionnaire about their cosmetic satisfaction

Have their skin examined, including photos and dermatoscopy

The results may help improve future treatment guidelines for people with non-melanoma skin cancer.professional, and any local recurrences will be identified through national health registries.

This nationwide study (DOSCA-2) will provide real-world data to help guide future treatment recommendations for NMSC.

Conditions

• Non-Melanoma Skin Cancer (NMSC)
• Basal Cell Carcinoma of Skin
• Squamous Cell Carcinoma of the Skin

Interventions

OTHER

Follow-up visit at least two years after treatment

In Denmark, people treated with primary radiotherapy for NMSC are not routinely offered a hospital follow-up visit to evaluate cosmetic results or recurrence. In this study, patients who received radiotherapy between 2020 and 2024 at five Danish cancer centers will be invited for a clinical examination at least two years after treatment. Cosmetic outcome will be rated by both the patient and a health professional, and any local recurrences will be identified through national health registries.

Sponsors & Collaborators

• Aarhus University Hospital

  collaborator OTHER

• Aalborg University Hospital

  collaborator OTHER

• Vejle Hospital

  collaborator OTHER

• Rigshospitalet, Denmark

  collaborator OTHER

• Copenhagen University Hospital at Herlev

  collaborator OTHER

• Danish Cancer Society

  collaborator OTHER

• University of Aarhus

  lead OTHER

Principal Investigators

• Jesper Grau Eriksen, Professor MD PhD · Department of Experimential Clinical Oncology, Aarhus University Hospital, Denmark

• Anita Gothelf, MD PhD · Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Denmark

• Pernille Lassen, MD PhD · Department of Oncology, Copenhagen University Hospital, Herlev, Denmark

• Rasmus Kjeldsen, MD · Department of Oncology, Aalborg University Hospital, Denmark

• Gulalai Hanan, MD · Department of Oncology, Vejle Hospital, Denmark

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-12-15

Primary Completion

2029-09-01

Completion

2029-09-01

Countries

• Denmark

Study Locations